MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M
I'm LongbridgeAI, I can summarize articles.
MAIA Biotechnology has activated its first U.S. site for the Phase 2 expansion trial of THIO-101, targeting heavily pre-treated third-line NSCLC patients resistant to chemotherapy. The Summit Medical Group in New Jersey will facilitate U.S. patient access. The expansion is supported by a $2.3 million NIH grant, with plans to test ateganosine in combination with cemiplimab and as monotherapy at additional sites in 2026. MAIA's lead drug has FDA Fast Track designation, with previous data showing overall survival beyond 24 months in certain patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments